Rennova Health, Inc. · OTC:RNVA
Rennova Health — IPO Roadshow (December 2016)
22 slides from Rennova Health's IPO roadshow presentation, Dec 9, 2016
Slide 1: Diagnostics and Supportive Software Solutions to Healthcare Providers
Filed Pursuant to Rule 433 Registration No. 333-214512 December 9, 2016 Nasdaq: RNVA, RNVAZ Diagnostics and Supportive Software Solutions to Healthcare Providers
Slide 2: Forward Looking Statements and Non-GAAP Information
Forward Looking Statements and Non-GAAP Information This presentation includes forward-looking statements about Rennova Health’s anticipated results that involve risks and uncertainties. Some of the information contained in this presentation, including statements as to industry trends and plans, obj
Slide 3: Free Writing Prospectus Statement
Free Writing Prospectus Statement This presentation highlights basic information about us and the proposed public offering. Because this presentation is a summary, it does not contain all of the information you should consider before investing in our securities. We have filed a registration statemen
Slide 4: Offering Summary
Offering Summary Issuer: Rennova Health, Inc. Exchange & Ticker: NASDAQ: RNVA Approximately $17,000,000 consisting of Convertible Preferred Stock Expected Offering Size: (plus a 15% over-allotment option) Redemption of outstanding convertible preferred stock; Working capital and general corporate pu
Slide 5: Healthcare is Being Transformed
Healthcare is Being Transformed We are Rennova Health 5
Slide 6: Key Investment Highlights
Key Investment Highlights • Five-year history of operations in clinical laboratory space and three years in software development for the medical sector • Capital investment in our Clinical Labs of approximately $8M • Own Labs in Florida, New Mexico, New Jersey, California and Connecticut • Adequate
Slide 7: Rennova Offers a Single Source Solution for Medical Providers
Rennova Offers a Single Source Solution for Medical Providers • The diagnostics sector has changed dramatically in the last few years • Paper records and faxes meant different vendors to a medical provider could function side by side without communication • Electronic platforms and integration have
Slide 8: Rennova Offers a Single Source Solution for Medical Providers
Rennova Offers a Single Source Solution for Medical Providers Clinical Lab Services 5 Clinical Laboratories Single Source Solution Revenue Software Cycle Solutions Management Proprietary Lab ordering and reporting Laboratory Information System (LIS) Integrated Medical Billing Company EHR / Practice
Slide 9: Recent Developments
Recent Developments Clinical Laboratory Operations Segment • We agreed to purchase Genomics, Inc. a biomedical diagnostics company that delivers personalized medicine by offering DNA-guided management and prescription of drugs used to treat mental illness, pain, heart disease and diabetes through a
Slide 10: Recent Developments
Recent Developments Supportive Software Solutions Segment • Our integrated software solution creates a much more sustainable relationship with our customers • EHR product launched in substance abuse sector last quarter 2015 • We believe we are on target to have secured approximately 100 EHR clients
Slide 11: Our Target Markets
Our Target Markets Drug and Alcohol Rehabilitation • Total Market Size – estimated at $35 Billion* • Large and growing number of facilities in a fragmented market • Between 14,500 to 16,700 outpatient clinics* Market growth from high demand: • Over 23 million Americans are addicted to alcohol and ot
Slide 12: Rennova Health Licensing Map
Rennova Health Licensing Map 12
Slide 13: Our Payers
Our Payers • Initiated Medicaid Licensing & Third Party Payer Initiative in December 2015 o Applied for Medicaid Licenses in 34 States o As of December 7, 2016, we possess Medicaid Licenses in 28 States • Current Third Party Insurance Payer Contracts o Blue Shield of California o Fortified Provider
Slide 14: History in Numbers
History in Numbers ($000’s) 70,000 59,429 60,000 50,000 41,889 37,877 40,000 28,921 30,000 19,749 20,000 14,775 10,000 6,904 1,386 0 (315) (10,000) (20,000) (19,517) (30,000) 2013 2014 2015 9 Months 2015 9 Months 2016 Adjusted Revenues Adjusted EBITDA 14
Slide 15: Select Income Statement Items
Select Income Statement Items 9 Months 9 Months (in thousands) 2013 2014 2015 2015 2016 GAAP Net Revenue $ 41,889 $ 57,928 $ 18,393 $ 28,921 $ 5,223 Reserve for Aged Accounts Receivable - 1,501 19,494 - 1,681 Adjusted Revenues $ 41,889 $ 59,429 $ 37,887 $ 28,921 $ 6,904 GAAP Pretax Income (Loss) $ 1
Slide 16: Strategy
Strategy 16
Slide 17: The Long Term Strategy
The Long Term Strategy Create a sustainable relationship with our customers to grow recurring revenue and provide value to our shareholders How? Build from a toxicology-focused company to: 1. A significant and diverse diagnostics business 2. Offering supportive software solutions that add value by g
Slide 18: 2017 Goals
2017 Goals • Strengthen Core Diagnostic Business o Plan to open our 1st hospital and include detox facility and clinical lab capabilities o Continue to capitalize on the disruption in toxicology sector o Increase Clinical testing o Grow Pharmacogenomics testing with Genomas o Launch DTC (Direct to C
Slide 19: Rennova Management
Rennova Management • 20 years experience in the restructuring, development Seamus Lagan and management of startup and small companies CEO • 20 years experience with public companies Marc Gelberg, CPA encompassing all aspects of financial management Director of Finance and SEC reporting and complianc
Slide 20: Board of Directors
Board of Directors • 20 years experience in the restructuring, development and Seamus Lagan management of startup and small companies CEO & Interim CFO • Founder, investor and shareholder • Chairman and CEO of Integrated Financial Settlements, Inc., Christopher Diamantis a structured settlement cons
Slide 21: Current Common Stock and Series G Preferred Stock
Current Shares Shares Outstanding Issuable Common Stock 56,384,594 56,384,594 Series G Preferred Stock 9,338 20,751,556 Convertible Debt 1,760,000 Warrants (weighted average exercise price of $0.44 per share) 35,368,284 Stock Options (weighted average exercise price of $4.25 per share) 22,199,174 13
Slide 22: Key Investment Highlights
Key Investment Highlights • Five-year history of operations in clinical laboratory space and three years in software development for the medical sector • Capital investment in our Clinical Labs of approximately $8M • Own Labs in Florida, New Mexico, New Jersey, California and Connecticut • Adequate